Cogstate Ltd smashed previous records with $89 million in net sales contracts for FY26, more than doubling the prior year. The company enters FY27 with a robust $118.5 million revenue backlog, signalling solid growth visibility.
- FY26 net sales contracts surged 116% to $89 million
- Contracted future revenue for FY27 up 32% to $118.5 million
- Revenue expected in FY27 rises 54% to $48.3 million
- Clinical Trials contracted revenue for FY27 jumps 58%
- Healthcare division revenue remains steady year-on-year
Record Sales Contracts Propel FY26 Growth
Cogstate Ltd (ASX:CGS) has delivered a standout performance in FY26, executing $89 million in net sales contracts; a leap of 116% compared to the $41.3 million secured in FY25. The June quarter alone contributed $21.9 million, maintaining strong momentum throughout the year. This surge reflects growing demand for Cogstate's neuroscience endpoint services, crucial in clinical trials assessing central nervous system therapies.
Expanding Revenue Backlog Signals FY27 Confidence
Entering FY27, Cogstate boasts a contracted future revenue pipeline of $118.5 million, up 32% from the prior year. Of this, $48.3 million is expected to be recognised as revenue during FY27, marking a 54% increase and providing enhanced earnings visibility. The company’s Clinical Trials division is the primary driver, with contracted revenue for FY27 rising 58% to $46.1 million. In contrast, Healthcare division contracted revenue remains flat at $2.3 million, indicating steady but unspectacular performance in that segment.
Clinical Trials Momentum Amid Revenue Recognition Lag
Cogstate’s sales contracts relate mainly to clinical research trials where its technology measures cognitive impact of investigational drugs. Revenue is recognised over the life of these contracts, often spanning multiple years, based on milestone achievements. This means the strong contract wins in FY26 will translate into revenue growth over subsequent years, with some lag between contract execution and revenue recognition. This dynamic underscores the importance of the company’s growing backlog, which underpins future revenue streams.
Investor Event to Detail Strategic Priorities
The company plans to release its audited FY26 Annual Report and Appendix 4E on 18 August 2026, followed by an investor call. Management will discuss FY26 results and outline FY27 priorities, including growth pillars, technology investments, and capital allocation plans. These details will be critical for investors assessing how Cogstate intends to sustain its rapid expansion and capitalise on its strong contract pipeline.
Bottom Line?
Cogstate’s record-breaking contract wins and expanding revenue backlog set a solid foundation for FY27, but the timing of revenue recognition will be key to watch.
Questions in the middle?
- How will Cogstate convert its large contract backlog into reported revenue throughout FY27?
- What specific growth initiatives will management prioritise following this strong contract performance?
- Can the Healthcare division regain momentum or will Clinical Trials continue to dominate revenue growth?